# Chat examples — 5 proteins × real questions and responses

Generated via `host.llm(claude-sonnet-5)` (equivalent to what the app calls via the Anthropic SDK). 
Retrieval pre-computes InterPro domain overlap for each aging region, so the LLM cites deterministic 
region→domain assignments rather than reasoning about intervals itself.

Source keys used in citations:
- **[S1]** UniProt
- **[S2]** InterPro
- **[S3]** AlphaFold
- **[S4]** WormBase
- **[S5]** This LiP-MS aging dataset (Sui et al.)
- **[S6]** This ML predictor
---

## VIT-6 (P18948)

### Q1. What is VIT-6 and where in its structure does aging cause the largest conformational change?

**VIT-6 (Vitellogenin-6)** is a 1,651-residue (193.3 kDa) yolk protein precursor in *C. elegans*. It functions as a nutrient reservoir for embryonic development, is a lipid transporter with a proposed role in cholesterol uptake, and has been implicated in thermotolerance [S1]. It is secreted and expressed specifically in the adult hermaphrodite intestine [S1, S4]. WormBase notes that VIT-6 is proteolytically cleaved in the body cavity into two smaller yolk proteins, YP115 and YP88 [S4]. Its domain architecture is built around the large Vitellogenin/Apolipophorin family fold (residues 1–1616), which contains an N-terminal vitellogenin domain (34–716), a superhelical lipovitellin-phosvitin domain (334–672), two lipid-transport beta-sheet shell regions (34–318 and 687–1063), an open beta-sheet vitellinogen domain (679–980), and a von Willebrand factor type D domain (1330–1515) [S2].

**Largest aging-associated conformational change:** Based on peptide-level LiP-MS measurements comparing day6 vs. day9 adults, the region with the single largest fold-change is **residues 454–500** (26 peptides, max |log2FC| = 4.477) [S5]. This region falls within the overlap of two domains: the Vitellogenin, N-terminal domain (IPR001747, spanning 34–716) and the Lipovitellin-phosvitin complex superhelical domain (IPR011030, spanning 334–672) [S1, S2, S5]. Structurally, this suggests the aging-related change is occurring within the superhelical (alpha-helical repeat) architecture that is thought to mediate lipid packaging in vitellogenin-family proteins, though the precise buried/exposed status of these residues would need to be checked against the AlphaFold model [S3] — that structural detail is not in the provided context.

Other substantial aging-changed regions, in descending order of peak magnitude, are:
- residues 912–1046 (69 peptides, max |log2FC|=3.444) — in the beta-sheet shell domain (687–1063) [S5, S2]
- residues 757–876 (72 peptides, max |log2FC|=3.337) — in the open beta-sheet vitellinogen domain (679–980) [S5, S2]
- residues 27–334 (152 peptides, max |log2FC|=3.247) — spans much of the N-terminal vitellogenin domain [S5, S2]
- residues 1082–1370 (74 peptides, max |log2FC|=3.032) — overlapping the vWF type D domain (1330–1515) [S5, S2]

Notably, the ML predictor independently flags residues 43–54 as its top-ranked positions on this protein (all p=1.0), and these are corroborated by observed LiP-MS data (max |log2FC|=2.758) [S6, S5] — this falls in the 27–334 region above, reinforcing that the N-terminal vitellogenin domain is a hotspot, even though it's not the single highest-magnitude region. Remember that the ML score is a prioritization/confidence score, not a direct measurement [S6].

No human orthologs or disease associations are curated for vit-6 in this context [S4], so no orthology-based disease interpretation can be offered here.


*Tokens: 3494 in / 1135 out · Citations: [S1], [S2], [S3], [S4], [S5], [S6] · stop: end_turn*

### Q2. Do the ML-predicted top residues overlap with the observed hotspots?

Yes — for vit-6, the ML predictor's top-ranked residues fall directly within one of the LiP-MS observed aging hotspots, and the model appears to essentially be flagging that same signal rather than pointing to new territory.

**Overlap details:**
- The top 10 ML-predicted residues (all p=1.0) are residues 43–54 [S6].
- This falls within the region **27–334** (152 peptides, max |log2FC|=3.247), one of the 5 contiguous aging-significant regions identified from day6/day9 LiP-MS comparisons [S5].
- That region 27–334 sits within the **Vitellogenin, N-terminal domain (IPR001747, 34–716)**, with a 301-aa overlap, and also within the broader **Vitellogenin/Apolipophorin family region (IPR050733, 1–1616)** [S1, S2].
- Consistent with this, each of the top 10 predicted residues is annotated `observed=True` with an observed max |log2FC| of 2.758 [S6, S5] — so the model's top picks are residues that were themselves measured to change conformationally with age, not purely extrapolated predictions.

**Interpretation and caveat:**
Structurally, residues 43–54 lie near the N-terminal end of the Vitellogenin N-terminal domain, close to where it begins (residue 34) [S1, S2] — consistent with this being an N-terminal region that shows strong aging-related LiP-MS signal (region 27–334, max |log2FC|=3.247 [S5]), though the single largest-magnitude hotspot overall is actually 454–500 (max |log2FC|=4.477 [S5]), which the top-10 ML list doesn't directly hit.

It's worth noting: the model score (p=1.0) is a prioritization/ranking output, not a measurement [S6] — here it happens to align tightly with an observed hotspot, but that agreement should be read as the model correctly flagging already-observed sites in this case, not as an independent validation of a novel unobserved site.


*Tokens: 3491 in / 675 out · Citations: [S5], [S6] · stop: end_turn*


---

## HSP-1 (P09446)

### Q1. What does HSP-1 do, and which regions change with age?

**Function**

hsp-1 (P09446) is the C. elegans HSP70A chaperone. UniProt itself carries no dedicated function line for this entry, but its GO annotations show it functions in ATP binding and ATP hydrolysis, as a protein folding chaperone, in protein refolding, in response to heat, in retrograde transport (endosome to Golgi), and in determination of adult lifespan [S1]. Structurally it has the classic Hsp70 architecture: an N-terminal ATPase (nucleotide-binding) domain spanning roughly residues 6-383 (built from two ATPase nucleotide-binding sub-regions, 6-188 and 192-383), a peptide-binding domain (386-544), and a C-terminal domain (539-620), all sitting within the overall Hsp70 family domain (6-613) [S2]. It is annotated as an HSP90 client protein, is highly abundant (log2 emPAI 10.8), and is ubiquitinated [context]. WormBase notes hsp-1 is broadly expressed and heat-inducible, and that RNAi knockdown modestly shortens lifespan in an age-1 mutant background, consistent with a role in longevity regulation [S4].

**Regions that change with age (LiP-MS)**

Across day6 vs day9 comparisons, 11 significant aging peptides cluster into 4 contiguous regions (|log2FC|>1, adj-p<0.05) [S5]:

- **Residues 541-551** — largest observed change (max |log2FC|=1.803, 4 peptides); falls at the start of the C-terminal domain superfamily region (539-620), just past the peptide-binding domain [S5, S2].
- **Residues 363-379** — max |log2FC|=1.433 (2 peptides); located within the second ATPase nucleotide-binding sub-domain (192-383), near the boundary with the peptide-binding domain [S5, S2].
- **Residues 611-640** — max |log2FC|=1.281 (2 peptides); this lies past the end of the annotated Hsp70 family domain (ends at 613) and the C-terminal domain superfamily (ends at 620), i.e., in the protein's extreme C-terminal tail, not covered by the InterPro domain calls listed [S5, S2].
- **Residues 425-448** — max |log2FC|=1.279 (3 peptides); within the peptide-binding domain superfamily (386-544) [S5, S2].

So the age-related conformational/proteolytic-susceptibility signal is concentrated at the ATPase/peptide-binding domain interface (363-379), within the substrate-binding domain itself (425-448), and heavily in the C-terminal lid/tail region (541-551 and 611-640) — consistent with age-related changes clustering toward the C-terminal half of the chaperone.

**ML predictions vs. observations**

The model's top-scored residues on this protein (629, 630, 635, 617-623, p≈0.48-0.57) all fall within or adjacent to the 611-640 region that was already observed as a significant aging peptide (max |log2FC|=1.281) [S6, S5]. Only 2 of 407 scored residues on this protein reach the p>0.5 high-confidence threshold, so these are prioritization scores flagging the extreme C-terminus for further attention — not independent measurements, and they should be read as reinforcing (not adding new territory to) the observed C-terminal aging signal [S6].

**Caveat on disease links**: the listed human orthologs (HGNC:5241, 5233, 5235) carry disease associations (e.g., cardiovascular disease, atherosclerosis, multiple sclerosis, major depressive disorder) purely by orthology inference — the context gives no evidence these relate mechanistically to the specific aging-changed regions above [context].


*Tokens: 3461 in / 1275 out · Citations: [S1], [S2], [S4], [S5], [S6] · stop: end_turn*

### Q2. Are the age-changed regions in known functional domains, and are there disease-linked human orthologs?

## Are the age-changed regions in known functional domains?

Three of the four significant aging-signal regions map directly onto annotated InterPro domains [S2, S5]:

- **Residues 541–551** (max |log2FC|=1.803, 4 peptides) — falls within the Heat shock protein 70 family domain (IPR013126, 6–613) and specifically within the **Hsp70 C-terminal domain superfamily** (IPR029048, 539–620) [S2, S5].
- **Residues 425–448** (max |log2FC|=1.279, 3 peptides) — within the HSP70 family domain and the **peptide-binding domain superfamily** (IPR029047, 386–544), i.e. the substrate-binding lobe of the chaperone [S2, S5].
- **Residues 363–379** (max |log2FC|=1.433, 2 peptides) — within the **ATPase nucleotide-binding domain** (IPR043129, 192–383), i.e. the nucleotide-binding lobe [S2, S5].

The fourth region, **residues 611–640** (max |log2FC|=1.281, 2 peptides), is not listed with a domain overlap in the context — the annotated Hsp70 C-terminal domain superfamily ends at residue 620, but no overlap tag is provided for this region, so based on the retrieved context I can't confirm domain assignment for it; it appears to sit in/near the extreme C-terminus, outside (or at the edge of) the last annotated domain [S2, S5]. Worth noting: this same C-terminal region is where the ML predictor's top-ranked residues cluster (residues 617–635, p=0.48–0.57, the model's only two high-confidence calls on this protein) [S6], and those flagged residues coincide with the observed 611–640 aging peptide (observed=True, |log2FC|=1.281) [S5, S6]. This is a prioritization score, not a measurement, but it reinforces that this C-terminal stretch is a region of interest by two independent lines of evidence.

So in summary: 3 of 4 aging-changed regions sit squarely in core Hsp70 functional domains (ATPase domain, peptide-binding domain, C-terminal domain), and the fourth is in the far C-terminal tail where the ML model also flags activity.

## Disease-linked human orthologs?

Yes — by orthology. The top-ranked human orthologs are HGNC:5241, HGNC:5233, and HGNC:5235 (each supported by 6–7 ortholog-prediction methods) [S4]. The associated disease list (via orthology, not direct evidence in worms) includes:

- Renal hypertension
- Familial hyperlipidemia
- Paranoid schizophrenia
- Cardiovascular system disease
- Major depressive disorder
- Cystic fibrosis
- Status epilepticus
- Atherosclerosis
- Brain ischemia
- Multiple sclerosis

These are broad, orthology-inferred disease associations for the human HSPA-family orthologs [S4] — not evidence that hsp-1 itself is linked to these conditions in *C. elegans*, and the context doesn't specify which orthology-prediction method(s) generated each specific disease link. If you want to trace which human paralog (HSPA1A/HSPA1B/HSPA8, etc.) maps to which disease, that would require checking the ortholog IDs directly on the linked databases beyond what's in this context.


*Tokens: 3473 in / 1623 out · Citations: [S4], [S6] · stop: end_turn*


---

## ACT-2 (P10984)

### Q1. Where in actin-2 does aging change the structure? How reliable are the ML predictions given the model card?

## Where aging changes structure in ACT-2

The LiP-MS dataset identifies 8 significant aging peptides (day6 vs day9, |log2FC|>1, adj-p<0.05) clustered in **3 contiguous regions** [S5]:

- **Residues 30–104** — the strongest signal, 6 peptides, max |log2FC| = 2.53. This region overlaps both the Actin family domain (IPR004000, res 4–376) and the N-terminal ATPase nucleotide-binding domain (IPR043129, res 4–154), with 75 aa of overlap in each case [S1, S2, S5]. It also contains an Actin conserved site (IPR004001, res 54–64) [S2]. This is by far the largest and most reliable aging-associated region, both in magnitude of change and peptide coverage.
- **Residues 363–373** — 1 peptide, max |log2FC| = 1.086, sitting in the C-terminal ATPase nucleotide-binding domain (IPR043129, res 148–376) and overlapping an Actin conserved site (IPR004001, res 357–365) [S2, S5].
- **Residues 248–255** — 1 peptide, max |log2FC| = 1.077, also within the C-terminal ATPase nucleotide-binding domain (IPR043129, res 148–376) [S2, S5].

Structurally, all three regions fall within the two lobes of actin's nucleotide-binding fold (the classic actin ATPase domain that binds ATP and coordinates the divalent cation) [S1, S2]. The 30–104 region is close to conserved actin-family sites and is part of the same domain architecture that spans nearly the whole protein (Actin family domain, res 4–376) [S2], consistent with an aging-related shift in protease accessibility near the nucleotide-binding cleft rather than an isolated surface loop — though the context doesn't specify which secondary-structure elements or solvent-exposure states these residues occupy, so I can't go further than domain-level placement.

## Reliability of the ML predictions

Per this protein's scoring, 311 residues were scored and only **1 residue reached high confidence (p>0.5)** — residue 46 (p=0.569), which sits within the 30–104 aging region and *was* independently observed in LiP-MS (observed max |log2FC| = 1.396) [S6, S5]. The rest of the top-10 list (residues 41–48, 249, 368) all cluster at moderate scores (p=0.397–0.483) and all correspond to residues already flagged as observed in the LiP-MS aging signal [S6]. In other words, on this protein the model isn't finding novel sites beyond what LiP-MS already detected — it's largely re-weighting the same experimentally observed region (30–104) plus the two smaller observed hits (249, 368).

Two caveats from the context: (1) these are **prioritization scores, not measurements** — a p-value here reflects model confidence that a residue is aging-relevant, not an effect size or statistical significance in the LiP-MS sense [S6]; (2) with only 1 of 311 scored residues crossing the 0.5 threshold on this protein, the model is not generating many confident calls for ACT-2 specifically — treat the moderate-probability residues (0.4–0.5 range) as weak-to-moderate leads rather than confident predictions. The context does not contain further detail on the model's calibration curves, training set composition, or cross-validation performance beyond what's summarized here — for that you'd want to consult the model card (app/MODEL_CARD.md) directly [S6].


*Tokens: 3228 in / 1190 out · Citations: [S2], [S5], [S6] · stop: end_turn*


---

## UNC-54 (P02566)

### Q1. UNC-54 is myosin — how widespread is the age-related conformational change, and where does the biggest signal fall?

Based on the LiP-MS aging data for UNC-54, the age-related conformational signal is fairly broad in span but concentrated in a modest fraction of the protein.

**Extent of the signal**
Out of 433 total unique peptides observed across all conditions, 127 significant aging peptides (day6 vs day9, |log2FC|>1, adj-p<0.05) were detected, organized into 5 contiguous regions [S5]. These regions are spread across both major structural modules of the protein — the motor (head) domain and the tail — rather than being confined to one part of the molecule:

- residues 187–232 (motor domain) [S5]
- residues 492–502 (motor domain) [S5]
- residues 1070–1080 (tail) [S5]
- residues 1315–1380 (tail) [S5]
- residues 1547–1578 (tail) [S5]

Given the protein's total length of 1963 aa, these 5 regions cover roughly 190 residues directly — a relatively small fraction of the sequence — but their distribution across both the Myosin head, motor domain-like region (IPR001609, 75–788) and the Myosin tail (IPR002928, 855–1932) [S1, S2] indicates the aging-related conformational change is not restricted to a single functional module.

**Where the biggest signal falls**
The single largest change is in the tail: residues 1315–1380 (7 peptides, max |log2FC|=2.595), overlapping 66 aa of the Myosin tail domain (IPR002928, 855–1932) [S5, S2]. This is notably the largest-magnitude and most peptide-rich of the five regions. The next largest signals are in the motor domain — residues 492–502 (max |log2FC|=2.269, 2 peptides) — and again in the tail at residues 1070–1080 (max |log2FC|=2.175, 2 peptides) [S5].

**Structural interpretation**
The myosin tail (IPR002928) forms the coiled-coil rod responsible for thick-filament assembly and dimerization, per the keyword annotation "Coiled coil" [S1]; a strong, high-confidence conformational change (|log2FC|=2.595) at residues 1315–1380 within this domain could plausibly reflect age-related destabilization of coiled-coil packing or filament-assembly regions, though the context does not contain direct structural data (e.g., solvent accessibility) to confirm whether this is a buried or exposed segment — that would need to be checked against the AlphaFold model [S3].

**Caveat on the ML predictions**
Separately, the ML predictor's top-ranked residues (144, 148, 150, 151, 199–204, all p=0.978) [S6] cluster in the N-terminal motor-domain region — near, but distinct from, the empirically observed 187–232 aging peptide region. Note these are prioritization scores, not measurements: residues 144/148/150/151 do have observed LiP-MS support (observed=True, max |log2FC|=1.459), but residues 199–204 are flagged as observed=False, meaning the model predicts them as aging-relevant despite no significant observed change there [S6]. This should be treated as a hypothesis-generating signal rather than confirmed evidence.


*Tokens: 3504 in / 1068 out · Citations: [S1], [S3], [S5], [S6] · stop: end_turn*

### Q2. How does the myosin-ts perturbation compare to the aging signal in this protein?

Based on the context provided, here's what I can extract:

**Peptide coverage under myosin-ts perturbation**
The dataset lists per-condition peptide counts for unc-54: myosin_ts_15 and myosin_ts_25 each have 108 unique peptides observed, compared to 267 for day6/day9 and 326 for hs, paramyosin_ts, and q35/q40 conditions [S5]. This means the myosin-ts conditions have substantially *lower peptide coverage* (108 vs 267-326) than the aging timepoints.

**What I can't tell you**
The context does not contain log2FC or significance values for the myosin_ts_15/myosin_ts_25 conditions themselves — the "AGING SIGNAL" section reports statistics only for day6 vs day9 comparisons (|log2FC|>1, adj-p<0.05, 127 significant peptides across 5 regions). There is no parallel differential-abundance or fold-change summary for the myosin-ts conditions in what was provided, so I cannot say whether the same regions (e.g., 1315-1380, 492-502, 1070-1080, 187-232, 1547-1578) show concordant, discordant, or absent structural changes under myosin-ts perturbation [S5].

**What this means practically**
Without peptide-level log2FC values for myosin_ts_15/25, I can't directly compare magnitude or directionality to the aging signal. What I *can* say is that the reduced peptide count (108) under myosin-ts conditions suggests either lower proteolytic/detection coverage in that condition or a different digestion/LiP outcome — but that's a coverage observation, not a structural or aging-relevant conclusion [S5].

**Suggestion**
If you want a real comparison, it would help to pull the peptide-level log2FC table for myosin_ts_15 and myosin_ts_25 (Table S1/S3) specifically for the same residue ranges flagged in the aging signal — particularly the two motor-domain regions (187-232, 492-502, both in the Myosin head, motor domain-like, IPR001609, 75-788 [S1, S2]) and the three tail regions (1070-1080, 1315-1380, 1547-1578, all in Myosin tail, IPR002928, 855-1932 [S1, S2]). That would let us see whether the myosin-ts (temperature-sensitive myosin mutant) background perturbs the same motor-domain and tail hotspots that change with age, which would be a mechanistically interesting link given unc-54 is itself the myosin heavy chain being perturbed.


*Tokens: 3493 in / 854 out · Citations: [S5] · stop: end_turn*


---

## DAF-16 (O16850)

### Q1. Does DAF-16 change with age in this dataset? If not, what should I look at instead?

Based on this dataset, **no** — DAF-16 does not show a detectable age-related conformational signal here.

**What the data show:**
- Only 2 unique LiP-MS peptides were observed for daf-16, and only under the `myosin_ts_15` and `myosin_ts_25` conditions [S5].
- In the aging comparison (day6 vs. day9, |log2FC|>1 and adj-p<0.05), **0 peptides** reached significance, across **0 contiguous regions** — there are no top regions to report [S5].
- No ML-predicted aging-relevant residues are available for this protein either (0 residues scored) [S6].

This most likely reflects a **coverage limitation rather than biological stability**: with only 2 peptides detected at all, and none under the actual aging (day6/day9) conditions, the protein's structural/proteolytic behavior over the aging timecourse simply wasn't sampled — daf-16 has fairly low abundance in this dataset (log2(emPAI) ≈ -1.58) [S5], which likely limited peptide detection. Absence of signal here should not be read as evidence that DAF-16 conformation is unchanged with age — the context does not contain information to distinguish "truly stable" from "undetected."

**What to look at instead:**
- **Domain-focused follow-up**: If you want to know whether the functionally critical Fork head DNA-binding domain (residues 173-268, with a conserved site at 224-230) [S1, S2] is behaved on with age, you'd need either (a) higher-depth LiP-MS data for daf-16 in future conditions, or (b) to check whether any of the 2 observed peptides overlap that domain — the context here doesn't specify peptide-level sequence positions, so I can't confirm that from what's given.
- **Pathway partners**: Since daf-16 activity is regulated post-translationally (nuclear/cytoplasmic shuttling, 14-3-3 binding via ftt-2, phosphorylation-state changes) rather than purely by abundance [S1], proteins in its regulatory network — e.g., upstream kinases or 14-3-3 partners — might show clearer LiP-MS aging signal and be more informative proxies for pathway activity than daf-16 itself.
- **Orthology angle**: If you're interested in disease relevance, the human orthologs (FOXO family, HGNC:3819/3821/7139) are linked by orthology to hepatocellular carcinoma, endometrial adenocarcinoma, Parkinson's disease, and others [S4] — worth checking if any of those orthologs' aging behavior is characterized in comparable datasets, though that's outside this context.

If you want, tell me another protein in the daf-16/IIS pathway (e.g., daf-2, age-1, akt-1/2) and I can check whether it has stronger LiP-MS aging coverage.


*Tokens: 4942 in / 950 out · Citations: [S1], [S4], [S5], [S6] · stop: end_turn*


---


## Summary

- **Proteins covered:** 5 — VIT-6, HSP-1, ACT-2, UNC-54, DAF-16
- **Total turns:** 8, all ended with `stop_reason=end_turn` (no truncation)
- **Total tokens:** 29,086 input / 8,770 output
- **Cost estimate:** ~$0.22 at Sonnet pricing (\$3/M input, \$15/M output)
- **Citation coverage:** every response cites ≥1 source from [S1]-[S6]; average 3.4 distinct sources per answer.